MAINZ The data also showed that the matched booster provided “a significant increase in neutralizing antibody responses against omicron variants BA.4/BA.5” compared to before the booster. This reaction was seen in adults under and over 55 years of age. The adapted vaccine is well tolerated. “The early data suggest a favorable safety profile similar to that of the original vaccine,” the statement said.
Additional data from this Phase 2/3 study is expected to be presented in the coming weeks. “These preliminary results are consistent with our preclinical data and show a substantial increase in the neutralizing antibody response directed against the omicron subvariants BA.4 and BA.5,” said Biontech CEO Ugur Sahin.
The BA.4/BA.5 booster has been approved in the EU since mid-September. However, clinical data on the effects on humans have not yet been available.
Tagus Top-Jobs
Find the best jobs now and
be notified by email.
/cloudfront-us-east-1.images.arcpublishing.com/prisaradioco/2YVA2IEXFNIIVHKYW2E7FHPKOA.jpg)
